Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

NASDAQ BCLI opened at $3.01 on Thursday. The firm’s fifty day simple moving average is $3.22 and its two-hundred day simple moving average is $3.28. Brainstorm Cell Therapeutics has a 12-month low of $2.75 and a 12-month high of $4.46. The firm has a market capitalization of $109.82 million, a P/E ratio of -4.43 and a beta of -0.04.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) last released its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. During the same quarter in the previous year, the business earned ($0.37) earnings per share. On average, analysts forecast that Brainstorm Cell Therapeutics will post -0.6 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCLI. Abner Herrman & Brock LLC lifted its holdings in shares of Brainstorm Cell Therapeutics by 13.7% during the first quarter. Abner Herrman & Brock LLC now owns 265,000 shares of the biotechnology company’s stock worth $890,000 after purchasing an additional 32,000 shares during the period. BlackRock Inc. increased its holdings in Brainstorm Cell Therapeutics by 0.7% in the 4th quarter. BlackRock Inc. now owns 472,476 shares of the biotechnology company’s stock worth $1,890,000 after buying an additional 3,509 shares during the period. Wells Fargo & Company MN increased its holdings in Brainstorm Cell Therapeutics by 40.8% in the 4th quarter. Wells Fargo & Company MN now owns 18,558 shares of the biotechnology company’s stock worth $74,000 after buying an additional 5,376 shares during the period. Geneos Wealth Management Inc. acquired a new position in Brainstorm Cell Therapeutics in the 4th quarter worth approximately $40,000. Finally, Weaver Consulting Group increased its holdings in Brainstorm Cell Therapeutics by 201.9% in the 4th quarter. Weaver Consulting Group now owns 155,500 shares of the biotechnology company’s stock worth $622,000 after buying an additional 104,000 shares during the period. 14.47% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics (Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Featured Stories